Semaglutide Cuts Heavy Drinking in Landmark Lancet Trial
The May 2026 Copenhagen trial is the largest RCT yet on GLP-1 drugs for alcohol use disorder — and the results clear the bar for a phase 3.
Semaglutide Cuts Heavy Drinking in Landmark Lancet Trial
The study: A research team led by Dr. Anders Fink-Jensen at Copenhagen University Hospital published results May 2, 2026 in The Lancet from a 26-week randomized controlled trial of once-weekly semaglutide (Ozempic/Wegovy) vs. placebo in 108 adults with alcohol use disorder (AUD) and comorbid obesity. It is the largest trial of a GLP-1 receptor agonist for AUD to date.
What they found: Heavy drinking days decreased significantly more in the semaglutide group than in the placebo group over the 26-week period. An earlier 9-week phase 2 trial (48 participants, 71% female) published in early 2026 found that semaglutide reduced grams of alcohol consumed (β=−0.48, P=.01), peak breath alcohol concentration (β=−0.46, P=.03), drinks per drinking day (β=−0.41, P=.04), and weekly craving (β=−0.39, P=.01) — with effect sizes at 0.5mg/week that are comparable to or exceed those of FDA-approved AUD medications (naltrexone, acamprosate).
The mechanism: GLP-1 receptor agonists appear to modulate dopamine reward pathways, reducing the motivational salience of alcohol and other rewarding stimuli. This is the same mechanism proposed for the drug’s effects on food intake — and, increasingly, on drugs other than alcohol.
Broader signal: A March 2026 BMJ analysis of 600,000+ U.S. veterans found that GLP-1 users had a 14–25% lower risk of developing SUDs across alcohol, opioids, cannabis, cocaine, and nicotine — a cross-substance finding suggesting systemic reward-pathway modulation rather than a substance-specific effect.
What’s not yet there: The FDA has not approved any GLP-1 for AUD treatment. Semaglutide can be prescribed off-label, particularly for patients who already qualify (obesity, Type 2 diabetes), but cost ($800–$1,000/month list price) remains a significant access barrier. Phase 3 trials are the logical next step.
Why This Matters for People in Recovery
Alcohol use disorder kills roughly as many Americans annually as drug overdoses — approximately 105,000 alcohol-induced deaths recorded in 2022. FDA-approved treatments (naltrexone, acamprosate, disulfiram) are chronically underutilized. If semaglutide’s signal holds in phase 3, it would be the first genuinely new pharmacological option for AUD in over two decades — and one that many patients are already taking for other indications.
Learn about alcohol use disorder and treatment options → | Find treatment near you →
Sources Cited
- 01.A
- 02.A
- 03.B
Filed Under
sciencetreatmentbiology
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
Psilocybin Lowered Inflammation Markers in Parkinson's Patients. Don't Let Anyone Tell You What That Proves.
A JAMA Psychiatry study reports lower inflammation markers in people with Parkinson's disease after psilocybin. It was small and had no control group. What it can and cannot tell clinicians.
Science & MedicineDoubling the THC Doesn't Double the High. So Why Is Everyone Selling It That Way?
A meta-analysis of 41 THC experiments finds that doubling the dose from 5 to 10 mg raised the self-reported high by about 15 percent and left anxiety unchanged. What it means for people who use, and for providers.
Science & MedicineTwo Postdocs Are Telling the DEA That Schedule I Is Not a Place to Park Uncertainty
Students for Sensible Drug Policy, two early-career scientists and MindState Design Labs asked the DEA for a hearing on placing five tryptamines in Schedule I. What the proposal covers, what it doesn't, and who it could hit first.